Last Updated on October 17, 2024 by The Health Master
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Fulvestrant injection, 250 mg/5 mL per Single-Dose Pre-filled Syringe (USRLD: Faslodex injection), a statement from Zydus said.
It also said that the (50 mg/mL) Fulvestrant injection is used alone, or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause.
The drug will be manufactured at the group’s formulation manufacturing facility at the Zydus Biologics, Ahmedabad, the statement added.
USFDA inspection ends with ‘Zero’ observations: Alkem
Granules Pharma clears USFDA audit
Zydus Cadila gets USFDA nod for Ibrutinib tablets
Lupin gets USFDA nod for generic Antifungal drug
Unichem gets tentative USFDA nod for drug to treat Diabetes
Alembic gets USFDA final nod for Erlotinib Tablets
CDSCO to regulate Cosmetic products like skin patches
Quality Medical Devices with low manufacturing cost a challenge
Rs 6 lakh per bottle in India: Roche launches spinal treatment…
USFDA inspection ends with ‘Zero’ observations: Alkem
NPPA fixes ceiling prices of 355 Medicines and 882 Formulations
Pharmexcil seeks list of products from Pharma Exporters
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
